By Sabela Ojea
Shares of Ardelyx rose after the company disclosed that its chairman, David Mott, has increased its stake in the company.
The stock was up 7.1%, to $5.41, in Wednesday post-market trading. Through the close, shares have dropped 41% over the past 12 months.
Mott, who has served as the biotechnology's chairman of the board since 2009, acquired 199,000 shares in the company, according to a Securities and Exchange Commission filing.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 22, 2025 18:25 ET (23:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.